Page last updated: 2024-11-04

chlordecone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Chlordecone, also known as Kepone, is a persistent organic pollutant (POP) that was formerly used as an insecticide. It was synthesized in the 1950s by the Allied Chemical Corporation and marketed as a pesticide for agricultural and industrial purposes. Chlordecone is highly lipophilic and persists in the environment for a long time, accumulating in soil, water, and living organisms. It is known to be toxic to humans and animals, causing a range of adverse health effects, including liver damage, reproductive problems, and cancer. Due to its toxicity and persistence, chlordecone was banned in the United States in 1975 and in most other countries. However, it continues to pose a threat to human health and the environment, particularly in areas where it was previously used. Research on chlordecone focuses on understanding its environmental fate and transport, its toxic effects on humans and wildlife, and potential methods for remediation and detoxification. It is also studied to assess the health risks associated with long-term exposure to low levels of the compound.'

Cross-References

ID SourceID
PubMed CID299
CHEMBL ID462576
CHEBI ID16548
SCHEMBL ID119101
MeSH IDM0011942

Synonyms (91)

Synonym
smr001261798
MLS002177806
ent-16391
nsc-124074
compound 1189
gc 1189
decachlorotetrahydro-4,7-methanoindeneone
general chemicals 1189
decachlorotetracyclodecanone
nci-c00191
merex
kepone-2-one, decachlorooctahydro-
clordecone
decachloroketone
1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2h-1,3,4-(methanetriyl)cyclobuta[cd]pentalen-2-one
1,2,3,4,6,7,8,9,10,10-decachloropentacyclo[5.3.0.0(2,6).0(3,9).0(4,8)]decan-5-one
perchloropentacyclo[5.3.0.0(2,6).0(3,9).0(4,8)]decan-5-one
CHEBI:16548 ,
decachloropentacyclo[5.2.1.0(2,6).0(3,9).0(5,8)]decan-4-one
nsc-56532
chlorodecone
S00336A
1,3,4-metheno-2h-cyclobuta[cd]pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-
NCGC00091008-01
NCGC00091008-02
chlordecone (kepone)
nsc 124074
2,3,3a,4,5,6,7,7a,8,8a-decachloro-3a,4,7,7a-tetrahydro-4,7-methanoinden-1-one
rcra waste no. u142
ent 16,391
ccris 128
1,2,3,4,5,5,6,7,8,9,10,10-dodecachlorooctahydro-1,3,4-metheno-2-cyclobuta(c,d)pentalone
1,2,3,5,6,7,8,9,10,10-decachloro(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decano-4-one
decachloropentacyclo(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decan-4-one
decachlorooctahydro-1,3,4-methano-2h-cyclobuta(cd)pentalen-2-one
rcra waste number u142
perchloropentacyclo(5.3.0.0(2,6).0(3,9).0(4,8))decan-5-one
decachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5),(8))decan-4-one
chlordecone [iso]
caswell no. 275
decachloropentacyclo(5.3.0.0(sup 2,6).0(sup 4,10).0(sup 5,9))decan-3-one
hsdb 1558
1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-1,3,4-metheno-2h-cyclobuta(cd)pentalen-2-one
epa pesticide chemical code 027701
einecs 205-601-3
ai3-16391
decachlorooctahydro-1,3,4-metheno-2h-cyclobuta(cd)pentalen-2-one
1,3,4-metheno-2h-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-
decachloro-1,3,4-metheno-2h-cyclobuta(cd)pentalen-2-one
kepone
143-50-0
C01792
chlordecone ,
NCGC00091008-03
1,2,3,4,6,7,8,9,10,10-decachloropentacyclo[5.3.0.02,6.03,9.04,8]decan-5-one
MLS002454392
CHEMBL462576
NCGC00091008-04
NCGC00091008-07
NCGC00091008-09
NCGC00091008-06
NCGC00091008-08
NCGC00091008-05
unii-rg5xj88udf
rg5xj88udf ,
dtxcid10770
NCGC00254136-01
NCGC00259141-01
dtxsid1020770 ,
tox21_201592
cas-143-50-0
tox21_300098
AKOS015950798
FT-0603353
chlordecone [mi]
chlordecone [hsdb]
chlordecone [iarc]
gc-1189
SCHEMBL119101
LHHGDZSESBACKH-UHFFFAOYSA-N
decachloropentacyclo(5.3.0.0(2,6).0(4,10).0(5,9))decan-3-one
decachlorpentacyclo (5.2.1.0(2,6).0(3,9).0(5,8)) decan-4-one
1,2,3,5,6,7,8,9,10,10-decachloro(5.2.1.0(2,6).0(3,9) .0(5,8))decan-4-one
1,3,4-metheno-2h-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachloroctahydro-
decachlorooctahydro-1,3,4-metheno-2h-cyclobuta[cd]pentalin-2-one
chlordecone, pestanal(r), analytical standard
bdbm50474727
kepone, analytical standard
chlordecone, 99%, vial of 1 g, (kepone equiv.)
J-007824
Q423892

Research Excerpts

Overview

Chlordecone is an endocrine-disrupting chemical with well recognized estrogenic and progestagenic properties. It was largely used as an insecticide to control a species of root borers, the Banana weevil (Cosmopolites sordidus), in the French West Indies, Guadeloupe and Martinique.

ExcerptReferenceRelevance
"Chlordecone is an endocrine-disrupting chemical with well recognized estrogenic and progestagenic properties. "(
Ayhan, G; Cordier, S; Costet, N; Giton, F; Kadhel, P; Michineau, L; Monfort, C; Multigner, L; Oliva, A; Rouget, F; Thomé, JP, 2021
)
2.06
"Chlordecone is an organochlorine that was largely used as an insecticide to control a species of root borers, the Banana weevil (Cosmopolites sordidus), in the French West Indies, Guadeloupe and Martinique. "( Visuospatial processing and fine motor function among 7-years old Guadeloupe children pre- and postnatally exposed to the organochlorine pesticide chlordecone.
Cordier, S; Desrochers-Couture, M; Kadhel, P; Michineau, L; Monfort, C; Muckle, G; Multigner, L; Rouget, F; Thomé, JP, 2022
)
2.36
"Chlordecone (CD; Kepone™) is a carcinogenic organochlorine insecticide with neurological, reproductive, and developmental toxicity that was widely used in the French West Indies (FWI) from 1973 to 1993 to fight banana weevils. "( Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments.
Emond, C; Multigner, L, 2022
)
3.61
"Chlordecone is a persistent organochlorine insecticide with estrogenic properties that was used in the French West Indies (1973-1993) and is still present in the soil and the water and food consumed by the local population."( Prenatal and childhood exposure to chlordecone and adiposity of seven-year-old children in the Timoun mother-child cohort study in Guadeloupe (French West Indies).
Cordier, S; Costet, N; Kadhel, P; Lafontaine, A; Michineau, L; Monfort, C; Multigner, L; Rouget, F; Thomé, JP, 2022
)
1.72
"Chlordecone is a highly persistent organochlorine insecticide that was intensively used in banana fields in the French West Indies, resulting in a widespread contamination. "( Prenatal and childhood chlordecone exposure, cognitive abilities and problem behaviors in 7-year-old children: the TIMOUN mother-child cohort in Guadeloupe.
Cordier, S; Desrochers-Couture, M; Kadhel, P; Michineau, L; Monfort, C; Muckle, G; Multigner, L; Oulhote, Y; Rouget, F; Thomé, JP, 2023
)
2.66
"Chlordecone (CLD) is an organochlorine pesticide (OCP) that is currently banned but still contaminates ecosystems in the French Caribbean. "( The Pesticide Chlordecone Promotes Parkinsonism-like Neurodegeneration with Tau Lesions in Midbrain Cultures and
Bizat, N; Haïk, S; Hunot, S; Lannuzel, A; Michel, PP; Parrales-Macias, V; Raisman-Vozari, R; Tourville, A, 2023
)
2.71
"Chlordecone is an organochlorine insecticide that has been used intensively from 1973 to 1993 in the French West Indies banana fields to control root borers. "( Chlordecone determination in serum by LC-MS/MS and the importance of low limit of detection.
El Balkhi, S; Saint-Marcoux, F, 2023
)
3.8
"Chlordecone (CLD) is an organochlorine pesticide widely used in the past to control pest insects in banana plantations in the French West Indies. "( Multi-scale impact of chronic exposure to environmental concentrations of chlordecone in freshwater cnidarian, Hydra circumcincta.
Abraldes, J; Benbrahim, K; Cerini, C; Colpaert, R; de Jong, L; Mambert, M; Moreau, X; Pique, V; Robin, M; Villard, PH, 2020
)
2.23
"Chlordecone (CLD) is a toxic organochlorine pesticide frequently used in the French West Indies until 1993, resulting in a contamination of soil and food. "( Effect of home cooking processes on chlordecone content in beef and investigation of its by-products and metabolites by HPLC-HRMS/MS.
Guérin, T; Lavison-Bompard, G; Lobo, F; Martin, D; Parinet, J, 2020
)
2.28
"Chlordecone (CLD) is a chlorinated persistent organic pollutant (POP) whose presence despite the 1993 ban in agriculture areas has caused numerous public health concerns. "( Affinity of chlordecone and chlordecol for human serum lipoproteins.
Cakir-Kiefer, C; Delannoy, M; Djelti, F; Girardet, JM; Yen, FT, 2020
)
2.38
"Chlordecone is an organochlorine pesticide, used in the Lesser Antilles from 1972 to 1993 to fight against a banana weevil. "( Contamination of marine fauna by chlordecone in Guadeloupe: evidence of a seaward decreasing gradient.
Bouchon, C; Bouchon-Navaro, Y; Cordonnier, S; Dromard, CR; Guéné, M; Lemoine, S, 2018
)
2.2
"Chlordecone is a persistent organochlorine pesticide that has been widely used in Guadeloupe (French West Indies) to control the banana weevil Cosmopolites sordidus from 1972 to 1993. "( Bioaccumulation, distribution and elimination of chlordecone in the giant freshwater prawn Macrobrachium rosenbergii: Field and laboratory studies.
Boulangé-Lecomte, C; Caupos, F; Dodet, N; Forget-Leray, J; Gismondi, E; Joaquim-Justo, C; Lafontaine, A; Lagadic, L; Lemoine, S; Thomé, JP, 2017
)
2.15
"Chlordecone is a persistent organochlorine pesticide used in the banana fields of the French West Indies from 1972 to 1993. "( Different transfer pathways of an organochlorine pesticide across marine tropical food webs assessed with stable isotope analysis.
Bouchon, C; Bouchon-Navaro, Y; Cordonnier, S; Dromard, CR; Guéné, M; Harmelin-Vivien, M, 2018
)
1.92
"Chlordecone is a synthetic organochlorine pesticide, extensively used in banana plantations of the French West Indies from 1972 to 1993. "( Distinct Carbon Isotope Fractionation Signatures during Biotic and Abiotic Reductive Transformation of Chlordecone.
Adrian, L; Barbance, A; Chevallier, ML; Cooper, M; Kümmel, S; Le Paslier, D; Richnow, HH; Saaidi, PL, 2018
)
2.14
"Chlordecone (CLD) is a Persistent Organic Pollutant used between 1972 until 1993 in the French West Indies (FWI). "( Validation of analytical methods for chlordecone and its metabolites in the urine and feces of ewes.
Bertin, T; Feidt, C; Fournier, A; Guérin, T; Inthavong, C; Lavison-Bompard, G; Parinet, J; Rychen, G; Saint-Hilaire, M, 2018
)
2.2
"Chlordecone is an organochlorine insecticide that was intensively used in the French West Indies to control the black weevil Cosmopolites sordidus in bananas. "( Chlordecone consumption estimated by sewage epidemiology approach for health policy assessment.
Amalric, L; Bristeau, S; Devault, DA, 2018
)
3.37
"Chlordecone is an organochlorine used in the 1970's as a pesticide in banana plantations. "( Chlordecone potentiates auto-immune hepatitis and promotes brain entry of MHV3 during viral hepatitis in mouse models.
Gelu-Simeon, M; Genet, V; Lamontagne, L; Piquet-Pellorce, C; Samson, M; Tabet, E, 2018
)
3.37
"Chlordecone (CD) is an insecticide that was used in the French West Indies for several years to control the banana root borer pest. "( Ovarian dysfunction following prenatal exposure to an insecticide, chlordecone, associates with altered epigenetic features.
D'Cruz, SC; Dali, O; Demmouche, A; Gely-Pernot, A; Hémery, C; Kernanec, PY; Kervarrec, C; Legoff, L; Multigner, L; Smagulova, F; Suglia, A; Tevosian, S, 2019
)
2.19
"Chlordecone (CLD) is an organochlorine pesticide used in banana fields of the French West Indies between 1972 and 1993. "( Linear toxicokinetic of chlordecone in ewe's serum.
Feidt, C; Fournier, A; Joaquim-Justo, C; Le Roux, Y; Rychen, G; Saint-Hilaire, M; Thomé, JP, 2020
)
2.31
"Chlordecone is an organochlorine pesticide that was extensively used to control the banana root borer population in the French West Indies until 1993. "( Chlordecone exposure and risk of congenital anomalies: the Timoun Mother-Child Cohort Study in Guadeloupe (French West Indies).
Cordier, S; Kadhel, P; Monfort, C; Multigner, L; Rouget, F; Thome, JP; Viel, JF, 2020
)
3.44
"Chlordecone is an organochlorine insecticide that has been widely used to control banana weevil in the French West Indies. "( Detection and quantification of chlordecone in contaminated soils from the French West Indies by GC-MS using the 13C10-chlordecone stable isotope as a tracer.
Lübke, M; Martin-Laurent, F; Merlin, C; Sahnoun, MM; Vollmer, G, 2014
)
2.13
"Chlordecone is a persistent organochlorine insecticide that, even decades after its ban, poses a threat to the environment and human health. "( Chlordecone fate and mineralisation in a tropical soil (andosol) microcosm under aerobic conditions.
Berns, AE; Disko, U; Fernández-Bayo, JD; Hofmann, D; Saison, C; Voltz, M, 2013
)
3.28
"Chlordecone is a very stable and recalcitrant molecule, mainly present in the solid phase, and has a strong affinity for organic matter."( Soil microstructure and organic matter: keys for chlordecone sequestration.
Carles, C; Clostre, F; Fernandes, P; Lesueur-Jannoyer, M; Rangon, L; Soler, A; Woignier, T, 2013
)
1.37
"Chlordecone is an organochlorine pesticide that has been extensively used to control the banana root borer population in the French West Indies."( Chlordecone exposure, length of gestation, and risk of preterm birth.
Cordier, S; Costet, N; Kadhel, P; Monfort, C; Multigner, L; Rouget, F; Thomé, JP, 2014
)
2.57
"Chlordecone is a persistent organochlorine pesticide that was used intensively, and almost exclusively, in the French West Indies until 1993."( Hypertensive disorders of pregnancy and gestational diabetes mellitus among French Caribbean women chronically exposed to chlordecone.
Cordier, S; Costet, N; Guldner, L; Kadhel, P; Monfort, C; Multigner, L; Rouget, F; Saunders, L; Thomé, JP, 2014
)
1.33
"Chlordecone is an organochlorine pesticide that was extensively used in the French West Indies to fight weevils in banana plantations from 1973 to 1993. "( Localization and in situ absolute quantification of chlordecone in the mouse liver by MALDI imaging.
Genet, V; Guével, B; Lagarrigue, M; Lavigne, R; Multigner, L; Pineau, C; Rondel, K; Samson, M; Tabet, E; Thomé, JP, 2014
)
2.1
"Chlordecone is a persistent organochlorine pesticide widely used between 1972 and 1993 in the French West Indies to control the root borer in banana fields. "( Expression of biotransformation and oxidative stress genes in the giant freshwater prawn Macrobrachium rosenbergii exposed to chlordecone.
Dodet, N; Gaume, B; Lemoine, S; Thomé, JP, 2015
)
2.07
"Chlordecone (Kepone) is an organochlorine insecticide that has been used as insecticide and fungicide. "( Chlordecone exposure and adverse effects in French West Indies populations.
Blanchet, P; Cordier, S; Kadhel, P; Multigner, L; Rouget, F, 2016
)
3.32
"Chlordecone is an organochlorine pesticide, used in the Lesser Antilles from 1972 to 1993 to fight against a banana weevil. "( Assessment of the contamination of marine fauna by chlordecone in Guadeloupe and Martinique (Lesser Antilles).
Bodiguel, X; Bouchon, C; Bouchon-Navaro, Y; Dromard, CR; Lemoine, S; Reynal, L; Thouard, E, 2016
)
2.13
"Chlordecone is an organochlorine pesticide (OCP) considered as a Persistent Organic Pollutant (POP) as it persists in the environment, bio-accumulates through the food web, causes adverse effects to human health and the environment and transports across international boundaries far from its sources. "( Ultra-trace quantification method for chlordecone in human fluids and tissues.
Antignac, JP; Bichon, E; Guiffard, I; Le Bizec, B; Marchand, P; Vénisseau, A, 2015
)
2.13
"Chlordecone (CLD) is an organochlorine pesticide whose extended use led to the contamination of at least 20% of agricultural soils from the French West Indies. "( Chlordecone disappearance in tissues of growing goats after a one month decontamination period--effect of body fatness on chlordecone retention.
Archimède, H; Feidt, C; Fournier, A; Jurjanz, S; Lastel, ML; Lerch, S; Mahieu, M; Rychen, G, 2016
)
3.32
"Chlordecone (CLD) is a persistent organic pollutant (POP) that was mainly used as an insecticide against banana weevils in the French West Indies (1972-1993). "( Chlordecone Transfer and Distribution in Maize Shoots.
Jamin, EL; Laurent, F; Létondor, C; Liber, Y; Pascal-Lorber, S, 2016
)
3.32
"Chlordecone is a chlorinated pesticide used in the 1990s."( Chlordecone potentiates hepatic fibrosis in chronic liver injury induced by carbon tetrachloride in mice.
Gelu-Simeon, M; Genet, V; Lucas-Clerc, C; Piquet-Pellorce, C; Samson, M; Tabet, E; Tiaho, F, 2016
)
2.6
"Chlordecone (CLD, Kepone) is an organochlorinated synthetic compound that has been used mainly as agricultural insecticide."( Theoretical study of chlordecone and surface groups interaction in an activated carbon model under acidic and neutral conditions.
Enriquez-Victorero, C; Gamboa-Carballo, JJ; Gaspard, S; Hernández-Valdés, D; Jáuregui-Haza, UJ; Melchor-Rodríguez, K; Montero-Alejo, AL, 2016
)
1.47
"Chlordecone (CLD) is an organochlorine insecticide abundant in aquatic environment of the French West Indies. "( Effects of chlordecone on 20-hydroxyecdysone concentration and chitobiase activity in a decapod crustacean, Macrobrachium rosenbergii.
Boulangé-Lecomte, C; Caupos, F; Dodet, N; Forget-Leray, J; Geraudie, P; Gismondi, E; Lafontaine, A; Lagadic, L; Lemoine, S; Thomé, JP, 2016
)
2.27
"Chlordecone is a persistent organochlorine pesticide widely used in Guadeloupe (French West Indies) to control the banana weevil Cosmopolites sordidus. "( Vitellogenin and vitellogenin receptor gene expression and 20-hydroxyecdysone concentration in Macrobrachium rosenbergii exposed to chlordecone.
Boulangé-Lecomte, C; Forget-Leray, J; Gismondi, E; Hanikenne, M; Lafontaine, A; Thomé, JP, 2016
)
2.08
"Chlordecone is a persistent organochlorine insecticide with well-defined estrogenic properties. "( Prenatal exposure to chlordecone, gestational weight gain, and birth weight in a Guadeloupean birth cohort.
Cordier, S; Costet, N; Hervé, D; Kadhel, P; Monfort, C; Multigner, L; Rouget, F; Thomé, JP, 2016
)
2.2
"Chlordecone (CLD) is a chlorinated hydrocarbon insecticide, now classified as a persistent organic pollutant. "( Two dechlorinated chlordecone derivatives formed by in situ chemical reduction are devoid of genotoxicity and mutagenicity and have lower proangiogenic properties compared to the parent compound.
Billat, PA; Bristeau, S; Clere, N; Faure, S; Legeay, S; Mouvet, C; Nesslany, F, 2018
)
2.26
"Chlordecone is a toxic organochlorine insecticide that was used in banana plantations until 1993 in the French West Indies. "( Determination of soil content in chlordecone (organochlorine pesticide) using near infrared reflectance spectroscopy (NIRS).
Achard, R; Barthès, BG; Brunet, D; Lesueur-Jannoyer, M; Rangon, L; Woignier, T, 2009
)
2.08
"Chlordecone is an organochlorine insecticide used in the French West Indies until 1993. "( Dietary exposure of 18-month-old Guadeloupian toddlers to chlordecone.
Cordier, S; Gillot, N; Héraud, F; Leblanc, JC; Loynet, C; Multigner, L; Reninger, JC; Rouget, F; Seurin, S; Volatier, JL, 2012
)
2.07
"Chlordecone is a persistent organochlorine pesticide that was used in the French West Indies until the early 1990s for banana weevil borer control. "( Exposure to an organochlorine pesticide (chlordecone) and development of 18-month-old infants.
Bataille, H; Boucher, O; Chajès, V; Cordier, S; Dallaire, R; Kadhel, P; Monfort, C; Muckle, G; Multigner, L; Rouget, F; Simard, MN; Thomé, JP, 2013
)
2.1
"Chlordecone is an organochlorine insecticide used until 1993 in the banana plantations of the French Antilles. "( Impact of subsistence production on the management options to reduce the food exposure of the Martinican population to Chlordecone.
Blateau, A; Dubuisson, C; Flamand, C; Gallotti, S; Héraud, F; Leblanc, JC; Quenel, P; Volatier, JL, 2007
)
1.99
"Chlordecone (Kepone) is a close structural analog of mirex, but it differs considerably from mirex in toxic action. "( Interaction of chlordecone with biological membranes.
Desaiah, D,
)
1.93
"Chlordecone (Kepone) is a decachloroketone analog of the dodecachlorohydrocarbon mirex and is used as a stomach poison insecticide. "( Chlordecone-induced hepatic dysfunction.
Mehendale, HM,
)
3.02
"Chlordecone or Kepone is a polycyclic chlorinated hydrocarbon insecticide that produces hyperexcitability, tremor, and other signs of nervous system toxicity. "( Chlordecone neurotoxicity: a brief overview.
Mactutus, CF; Tilson, HA, 1982
)
3.15
"Chlordecone is an organochlorine insecticide which intoxicated a number of workers in 1975 because of excessive exposure in the industrial plant. "( Neurological manifestations in humans exposed to chlordecone and follow-up results.
Taylor, JR, 1982
)
1.96
"Chlordecone (CD) is an organochlorine pesticide associated with albumin and high-density lipoproteins (HDL) in the plasma. "( High-density lipoproteins decrease the biliary concentration of chlordecone in isolated perfused pig liver.
Blanke, RV; Chinchilli, VM; Schwartz, CC; Soine, PJ, 1984
)
1.95
"Chlordecone (Kepone) is a polychlorinated hydrocarbon that has a low affinity for the estrogen receptor. "( Estradiol-chlordecone (Kepone) interactions: additive effect of combinations for uterotropic and embryo implantation functions.
Johnson, DC, 1996
)
2.14
"Chlordecone (Kepone) is a lipophilic, rodent liver carcinogen which now stands among the most extensively studied environmental agents in humans."( The clinical toxicology of chlordecone as an example of toxicological risk assessment for man.
Guzelian, PS, 1992
)
1.3

Effects

Chlordecone has known hormonal properties and exposure through contaminated food during critical periods of development (gestation and early infancy) may affect growth. It has been found in the blood of pregnant women and in cord blood.

ExcerptReferenceRelevance
"Chlordecone has been detected in diverse marine organisms in the Caribbean, but unexpectedly, also in French Polynesia."( Exposure to the environmentally-persistent insecticide chlordecone induces detoxification genes and causes polyp bail-out in the coral P. damicornis.
Berteaux-Lecellier, V; Bonnard, I; Guibert, I; Lecellier, G; Wecker, P; Zhou, Y, 2018
)
1.45
"Chlordecone has known hormonal properties and exposure through contaminated food during critical periods of development (gestation and early infancy) may affect growth."( Perinatal exposure to chlordecone and infant growth.
Bataille, H; Bodeau-Livinec, F; Comets, E; Cordier, S; Costet, N; Kadhel, P; Linganiza, EM; Monfort, C; Multigner, L; Pelé, F; Rouget, F, 2015
)
1.45
"Chlordecone has been found in the blood of pregnant women and in cord blood."( Prenatal exposure to chlordecone, gestational weight gain, and birth weight in a Guadeloupean birth cohort.
Cordier, S; Costet, N; Hervé, D; Kadhel, P; Monfort, C; Multigner, L; Rouget, F; Thomé, JP, 2016
)
1.47
"Chlordecone has been shown to impair neurological and behavioural functions in rodents when exposed gestationally or neonatally."( Cognitive, visual, and motor development of 7-month-old Guadeloupean infants exposed to chlordecone.
Bataille, H; Boucher, O; Chajès, V; Cordier, S; Dallaire, R; Guldner, L; Jacobson, SW; Kadhel, P; Monfort, C; Muckle, G; Multigner, L; Rouget, F; Seurin, S; Thomé, JP, 2012
)
1.32
"Chlordecone has been reported to resemble estrogen in altering pituitary secretions, in producing vaginal cornification, in increasing uterine weight and in competing for binding to the estrogen receptor."( Failure of chlordecone (Kepone) to induce behavioral estrus in adult ovariectomized rats.
Brown, H; Eckols, K; Kolodziej, M; Sierra, V; Uphouse, L, 1986
)
1.38
"Chlordecone (Kepone) has been extensively studied for its toxicity in male production workers who were exposed to large quantities of this organochlorine pesticide. "( Evaluation of chlordecone in a two-stage model of hepatocarcinogenesis: a significant sex difference in the hepatocellular carcinoma incidence.
Blanke, RV; Fitzgerald, R; Guzelian, PS; Sirica, AE; Wilkerson, CS; Wu, LL, 1989
)
2.08

Actions

Chlordecone does not cause liver injuries or any inflammation by itself at low doses, but it can potentiate the hepatotoxic effects of other chemicals and drugs. Chlordecones induced more increase in these serum components of rats fed with Ca-D as compared to Ca-S diet.

ExcerptReferenceRelevance
"Chlordecone does not cause liver injuries or any inflammation by itself at low doses, but it can potentiate the hepatotoxic effects of other chemicals and drugs."( Chlordecone potentiates auto-immune hepatitis and promotes brain entry of MHV3 during viral hepatitis in mouse models.
Gelu-Simeon, M; Genet, V; Lamontagne, L; Piquet-Pellorce, C; Samson, M; Tabet, E, 2018
)
2.64
"Chlordecone induced more increase in these serum components of rats fed with Ca-D as compared to Ca-S diet."( Influence of dietary calcium on chlordecone-induced biochemical changes in serum of rat.
Brown, K; Chetty, KN; Ivie, GW; Walker, J, 1993
)
1.29

Treatment

Chlordecone treatment in (NZBxNZW) F(1) mice shortened significantly the time to onset of elevated autoantibody titers and renal disease. The treatment led to the presence of vaginal estrus within 2 days, but reduced or eliminated sexual behavior on the evening of predicted proestrus.

ExcerptReferenceRelevance
"Chlordecone treatment in (NZBxNZW) F(1) mice shortened significantly the time to onset of elevated autoantibody titers and renal disease in a dose-related manner."( Comparison of chlordecone effects on autoimmunity in (NZBxNZW) F(1) and BALB/c mice.
Butfiloski, E; Croker, B; Roberts, SM; Sobel, ES; Wang, F, 2006
)
1.42
"Chlordecone treatments produced dose-dependent cell surface changes in the reproductive tract that were either characteristic of estrogenic stimulation or atypical responses."( Surface changes in oviduct, uterus and vaginal cells of neonatal mice after estradiol-17 beta and the insecticide chlordecone (Kepone) treatment: a scanning electron microscopic study.
Eroschenko, VP, 1982
)
1.2
"Chlordecone pretreatment enhanced the severity of the CHCl3-induced cellular changes and increased the number of cells affected."( A semiquantitative morphologic assessment of chlordecone-potentiated chloroform hepatotoxicity.
Côté, MG; Iijima, M; Plaa, GL, 1983
)
1.25
"Chlordecone treatment produced a dose dependent suppression of food intake."( Effects of chlordecone on food intake and body weight in the male rat.
Montanez, S; Uphouse, L; Williams, J, 1992
)
1.39
"Chlordecone (CD) treatment of rat liver plasma membranes (LPM) provided in vitro evidence for mechanisms of in vivo liver dysfunction caused by CD. "( Chlordecone impairs Na(+)-stimulated L-[3H]glutamate transport and mobility of 16-doxyl stearate in rat liver plasma membrane vesicles.
Curtis, LR; Miller, TL; Rochelle, LG, 1990
)
3.16
"Chlordecone (CD) pretreatment is well known to greatly potentiate CCl4 toxicity. "( Protection from chlordecone-amplified carbon tetrachloride toxicity by cyanidanol: biochemical and histological studies.
Mehendale, HM; Soni, MG, 1991
)
2.07
"Chlordecone treatment led to the presence of vaginal estrus within 2 days, but reduced or eliminated sexual behavior on the evening of predicted proestrus."( Vaginal cyclicity, sexual receptivity, and eating behavior of the female rat following treatment with chlordecone.
Uphouse, L; Williams, J, 1991
)
1.22
"Chlordecone-treated rats showed a significant reduction in calmodulin levels in brain P2 fraction."( Chlordecone inhibition of calmodulin activated calcium ATPase in rat brain synaptosomes.
Chetty, CS; Desaiah, D; Rao, KS, 1985
)
2.43
"Chlordecone (CD) pretreatment is known to markedly potentiate CCl4 hepatotoxicity. "( Protection of chlordecone-potentiated carbon tetrachloride hepatotoxicity and lethality by partial hepatectomy.
Bell, AN; Lockard, VG; Mehendale, HM; Young, RA, 1988
)
2.08
"Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls."( Potentiation of carbon tetrachloride hepatotoxicity by chlordecone: dose-response relationships and increased covalent binding in vivo.
Britton, RS; Dolak, JA; Glende, EA; Recknagel, RO, 1987
)
1.24
"Chlordecone treatment of rats induced progesterone receptors in uterus of immature rats, but not in uterus of ovariectomized adult rats."( Effects of chlordecone on progesterone receptors in immature and adult rats.
Eckols, K; Uphouse, L; Williams, J, 1989
)
1.39
"Chlordecone pretreatment alone had no effect on the kinetics of calcium uptake by hepatic microsomes."( Potentiation by chlordecone of the defect in hepatic microsomal calcium sequestration induced by carbon tetrachloride.
Glende, EA; Hegarty, JM; Recknagel, RO, 1986
)
1.34
"Treatment with chlordecone, methoxychlor, or o,p -dichlorodiphenyltrichloroethane (o,p -DDT) significantly decreased the time to onset of renal impairment, as did treatment with 17ss-estradiol used as a positive control."( Acceleration of autoimmunity by organochlorine pesticides in (NZB x NZW)F1 mice.
Butfiloski, EJ; Croker, BP; Gianini, J; Roberts, SM; Schiffenbauer, J; Sobel, ES, 2005
)
0.67
"Rats treated with chlordecone for 10 days showed a significant reduction of Na+-K+ ATPase activity in brain and kidney."( Chlordecone toxicity: effect of withdrawal of treatment on ATPase inhibition.
Bansal, SK; Desaiah, D, 1985
)
2.04
"Treatment with chlordecone resulted in a two- to three-fold increase in cytochrome P-450 content but the BP-hydroxylase activity per mg microsomal protein was unaffected."( Influence of chlordecone and mirex exposure on benzo[a]pyrene metabolism of rat-liver microsomes.
Crouch, LS; Ebel, RE, 1987
)
0.98

Toxicity

Chlordecone sensitizes the liver in ovariectomized rats as well to amplify the toxic effects of CCl4. Dosages of 5 mg/kg did not potentiate CHCl3 toxicity, but higher dosages enhanced the toxic response in a dose-dependent manner. retardation in the population growth were observed in response to chlordec one and fipronil in both rotifer species.

ExcerptReferenceRelevance
" Oligomycin-sensitive Mg2(+)-ATPase was decreased significantly only starting at 6 hr (21%) after CCl4 administration, indicating that depletion of ATP at early time points was most likely due to rapid utilization consequent to toxic events."( Altered hepatic energy status in chlordecone (Kepone)-potentiated CCl4 hepatotoxicity.
Kodavanti, PR; Kodavanti, UP; Mehendale, HM, 1990
)
0.56
" Since CCl4 is toxic by virtue of its bioactivation by the hepatomicrosomal cytochrome P-450 (cyt P-450) system, which is in turn destroyed, our first interest was to determine if cyt P-450 isozymes were selectively destroyed in this interaction."( Amplification of CCl4 toxicity by chlordecone: destruction of rat hepatic microsomal cytochrome P-450 subpopulation.
Chaudhury, S; Mehendale, HM, 1991
)
0.56
"A major toxicological issue today is the possibility of unusual toxicity due to interaction of toxic chemicals upon environmental or occupational exposures to two or more chemicals, at ordinarily harmless levels individually."( Potentiation of halomethane hepatotoxicity by chlordecone: a hypothesis for the mechanism.
Mehendale, HM, 1990
)
0.54
" CD, known to potentiate hepatotoxic and lethal effects of halomethanes in rats, failed to potentiate the toxic effects of any of these three halomethanes in gerbils."( Hepatotoxicity and lethality of halomethanes in Mongolian gerbils pretreated with chlordecone, phenobarbital or mirex.
Cai, Z; Mehendale, HM, 1991
)
0.51
" These findings suggest that the suppression of stimulated hepatocellular regeneration results in the loss of the essential mechanism of tissue repair leading to continuation of the toxic liver injury associated with the CD + BrCCl3 combination treatment."( Potentiation of BrCCl3 hepatotoxicity by chlordecone: biochemical and ultrastructural study.
Faroon, OM; Henry, RW; Mehendale, HM; Soni, MG, 1991
)
0.55
" For comparison, a large toxic dose of CCl4 was also employed."( Hepatic polyamines and related enzymes following chlordecone-potentiated carbon tetrachloride toxicity in rats.
Mehendale, HM; Rao, SB; Young, RA, 1989
)
0.53
" These results indicate that photomirex was approximately five times more toxic than mirex in terms of liver histology."( Subchronic toxicity of photomirex in the female rat: results of 28- and 90-day feeding studies.
Becking, GC; Chu, I; Secours, V; Sundaram, A; Villeneuve, DC, 1980
)
0.26
"Plasma and brain levels of chlordecone in chlordecone-induced motor impairment, lethal levels of chlordecone, and cumulative LD50 of chlordecone in the mouse are presented."( Neurochemical evaluation of chlordecone toxicity in the mouse.
Chang-Tusi, H; Fujimori, K; Ho, IK; Huang, TP,
)
0.72
" Forty-eight hour LD50 of CCl4 was decreased 26-fold by CD pretreatment."( Potentiation of CCl4 hepatotoxicity and lethality by chlordecone in female rats.
Agarwal, AK; Mehendale, HM,
)
0.38
" The LD50 were determined by the method of moving averages."( Acute hepatotoxicity and lethality of CCl4 in chlordecone-pretreated rats.
Klingensmith, JS; Lockard, V; Mehendale, HM, 1983
)
0.52
" Effect of CD on 48 hr LD50 of BrCCl3 was also examined using the method of moving averages."( Potentiation of bromotrichloromethane hepatotoxicity and lethality by chlordecone preexposure in the rat.
Agarwal, AK; Mehendale, HM,
)
0.37
" Dosages of 5 mg/kg of chlordecone did not potentiate CHCl3 toxicity, but higher dosages (10-50 mg/kg) enhanced the toxic response in a dose-dependent manner."( A semiquantitative morphologic assessment of chlordecone-potentiated chloroform hepatotoxicity.
Côté, MG; Iijima, M; Plaa, GL, 1983
)
0.84
" This study suggests that chlordecone sensitizes the liver in ovariectomized rats as well to amplify the toxic effects of CCl4."( Chlordecone potentiation of CCl4 hepatotoxicity in ovariectomized rats.
Agarwal, AK; Mehendale, HM, 1984
)
2.01
" Ca2+ in whole liver, mitochondria, microsomes or in cytosolic fraction was unaltered in any group of animals receiving chlordecone + oil treatments, indicating that chlordecone alone does not alter whole liver content or hepatic subcellular distribution of Ca2+, even after exposure to toxic levels (50 or 100 ppm)."( Excessive hepatic accumulation of intracellular Ca2+ in chlordecone potentiated CCl4 toxicity.
Agarwal, AK; Mehendale, HM, 1984
)
0.72
" It appears that a greater bioactivation of CCl4 in chlordecone treated animals resulted in an initial potentiation of toxic events in the liver cells."( Potentiation of halomethane hepatotoxicity: chlordecone and carbon tetrachloride.
Mehendale, HM, 1984
)
0.78
"Why is a low dose of toxic chemical nontoxic? What makes a larger dose of the same chemical toxic? Extensive work done to understand the mechanism of halomethane hepatotoxicity and its potentiation by chlorinated insecticide, chlordecone has resulted in the understanding of these basic tenets of toxicology."( Halomethane-chlordecone (CD) interactive hepatotoxicity--current concepts on the mechanism.
Mehendale, HM; Rao, SB, 1993
)
0.85
"It is often assumed that at a younger age populations are at higher risk of toxic effects from exposure to toxic chemicals."( Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl4 hepatotoxicity.
Dalu, A; Mehendale, HM, 1996
)
0.52
"Xenobiotics may cause long-term adverse effects in humans, especially at the embryonic level, raising questions about their levels of exposure, combined effects, and crucial endpoints."( Cytotoxic effects and aromatase inhibition by xenobiotic endocrine disrupters alone and in combination.
Benachour, N; Moslemi, S; Seralini, GE; Sipahutar, H, 2007
)
0.34
" Moreover, retardation in the population growth were observed in response to chlordecone and fipronil in both rotifer species, suggesting that chlordecone and fipronil have a potential adverse effects on life cycle parameters of two rotifer species."( Adverse effects of the insecticides chlordecone and fipronil on population growth and expression of the entire cytochrome P450 (CYP) genes in the freshwater rotifer Brachionus calyciflorus and the marine rotifer Brachionus plicatilis.
Han, J; Hwang, UK; Lee, JS; Lee, YH; Park, JC, 2018
)
0.98

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic investigations incorporating such models are illustrated for two halogenated hydrocarbons that exhibit different patterns of disposition in the rat: 2,2',4,4',5,5'-hexachlorobiphenyl and Kepone."( Pharmacokinetics of halogenated hydrocarbons.
Bungay, PM; Dedrick, RL; Matthews, HB, 1979
)
0.26
" Tissue dosimetry at the pharmacokinetic and pharmacodynamic levels is achievable with simple and complex, but chemically defined, mixtures."( Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.
Benjamin, SA; el-Masri, HA; Thomas, RS; Yang, RS, 1995
)
0.29
" A pharmacodynamic estrus cycle (PD-EC) model for the Sprague-Dawley rats has been developed in an attempt to analyze the physiological basis of early-onset persistent estrus and to examine the potential sites of interactions in the hypothalamic-pituitary-ovarian axis for endocrine-modulating xenobiotics that accelerate the onset of persistent estrus."( Pharmacodynamic model of the rat estrus cycle in relation to endocrine disruptors.
Allen, BC; Andersen, ME; Barton, HA; Clewell, HJ; Gearhart, J, 1997
)
0.3
" The aims of this study were to develop a physiologically based pharmacokinetic (PBPK) model in the rat and extrapolate it to humans based on available pharmacokinetic data in the literature."( Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments.
Emond, C; Multigner, L, 2022
)
2.16

Bioavailability

ExcerptReferenceRelevance
" These results indicate that chlordecone is well absorbed and distributed throughout the body, has a long half-life, and disappears more slowly from the liver than from other tissues."( Distribution and excretion of chlordecone (Kepone) in the rat.
Borzelleca, JF; Egle, JL; Fernandez, JB; Guzelian, PS,
)
0.71
" The impact of soil type on CLD bioavailability to hens was tested through a relative bioavailability study."( Relative bioavailability of tropical volcanic soil-bound chlordecone in laying hens (Gallus domesticus).
Bouveret, C; Feidt, C; Jondreville, C; Lesueur-Jannoyer, M; Rychen, G, 2013
)
0.64
" The aim of this study was to assess the impact of two tropical volcanic soils, an andosol and a nitisol, on CLD availability in piglets, using the relative bioavailability (RBA) approach."( Relative bioavailability of tropical volcanic soil-bound chlordecone in piglets.
Bouveret, C; Feidt, C; Jondreville, C; Lerch, S; Rychen, G, 2013
)
0.64
" Indeed, measured concentrations could be integrated in a lowered extent if the soil binding would reduce the bioavailability of the pesticide."( Relative bioavailability of soil-bound chlordecone in growing lambs.
Archimède, H; Feidt, C; Fournier, A; Jondreville, C; Jurjanz, S; Mahieu, M; Rychen, G, 2014
)
0.67
" The objective of this study was to evaluate the absorption rate and the half-life of CLD in the non-lactating goat."( Toxicokinetics of chlordecone in goats: Implications for risk management in French West Indies.
Archimede, H; Feidt, C; Fournier, A; Lastel, ML; Mahieu, M; Rychen, G; Thome, JP, 2017
)
0.79
" In that context, sequestering matrices like biochars or activated carbons (ACs) are believed to efficiently decrease the bioavailability of such compounds when added to contaminated soils."( Amendment of soil by biochars and activated carbons to reduce chlordecone bioavailability in piglets.
Baroudi, M; Caria, G; Delannoy, M; Feidt, C; Montargès-Pelletier, E; Razafitianamaharavo, A; Richard, A; Rychen, G; Techer, D; Yehya, S, 2018
)
0.72
" In that context, sequestering matrices like activated carbons (ACs) may be used to efficiently decrease the bioavailability of such organic pollutants."( Evaluation of two contrasted activated carbon-based sequestration strategies to reduce soil-bound chlordecone bioavailability in piglets.
Amutova, F; Baroudi, M; Delannoy, M; Feidt, C; Fournier, A; Montarges-Pelletier, E; Razafitianamaharavo, A; Rychen, G; Techer, D; Yehya, S, 2020
)
0.78
" In that context, carbonaceous materials may be used to amend soil to efficiently decrease the bioavailability of such organic pollutants."( In vitro and in vivo assessment of a CLD sequestration strategy in Nitisol using contrasted carbonaceous materials.
Baroudi, M; Delannoy, M; El Wanny, N; Feidt, C; Gaspard, S; Ranguin, R; Rychen, G; Yacou, C, 2022
)
0.72
" Thus, (i) biochars were not proven efficient to reduce halogenated pollutants transfer to animals, (ii) powdered AC amendments resulted in reducing the bioavailability of soil POPs, and (iii) the effectiveness of such strategy depended on both characteristics of the matrix and of the pollutants."( Organochlorine POPs sequestration strategy by carbonaceous amendments of contaminated soils: Toward a better understanding of the transfer reduction to laying hens.
Baroudi, M; Delannoy, M; El Wanny, N; Feidt, C; Fournier, A; Le Roux, Y; Woignier, T, 2022
)
0.72

Dosage Studied

The immunotoxic potential of chlordecone was evaluated in male Fischer-344 rats following 10 d of acute dosing by oral gavage. In most animals, sexual behavior, both receptivity and proceptivity, was reduced within 60 min following the higher dosage. Body weight loss was significant by 90 days of dosing with 30 ppm chlordicone.

ExcerptRelevanceReference
" More than five years of clinical investigations of workers heavily exposed to organochlorine pesticide have established the spectrum of human toxicity of Chlordecone, its dose-response relationships, tissue distribution, metabolic pathways, half-time for elimination, and the concentration at which its major toxic manifestations involving the central nervous system, the liver, and the testes are not observed (no observable effect level, NOEL)."( The clinical toxicology of chlordecone as an example of toxicological risk assessment for man.
Guzelian, PS, 1992
)
0.78
" Female Sprague-Dawley rats were orally dosed with mirex (12."( Mirex exposure inhibits the uptake of estradiol-17 beta(beta-D-glucuronide), taurocholate, and L-alanine into isolated rat hepatocytes.
Teo, S; Vore, M, 1990
)
0.28
" Male Sprague-Dawley rats were orally dosed with corn oil, mirex (50 mg/kg), or chlordecone (18."( Mirex inhibits bile acid secretory function in vivo and in the isolated perfused rat liver.
Teo, S; Vore, M, 1991
)
0.51
" In most animals, sexual behavior, both receptivity and proceptivity, was reduced within 60 min following the higher dosage of chlordecone."( Chlordecone (Kepone) on the night of proestrus inhibits female sexual behavior in CDF-344 rats.
Brown, HE; Salamanca, S; Stewart, G; Uphouse, L, 1991
)
1.93
" When using 12 concentration levels, one of the logistic family two- or three-parameter models was shown reliably to represent each of these various sets of dose-response data, and to provide adequate estimates of EC01 and EC05, as well as EC10 and EC50."( A study of the shape of dose-response curves for acute lethality at low response: a "megadaphnia study".
Adams, WJ; Sebaugh, JL; Tucker, MW; Wilson, JD, 1991
)
0.28
"The immunotoxic potential of chlordecone was evaluated in male Fischer-344 rats following 10 d of acute dosing by oral gavage."( Evaluation of the immunotoxic potential of chlordecone with comparison to cyclophosphamide.
Luebke, RW; Riddle, MM; Rogers, RR; Rowe, DG; Smialowicz, RJ, 1985
)
0.82
" Following the pretreatment at various time intervals ranging from 10 to 96 hr, groups of animals received a challenging dosage of CHCl3 (0."( Modifications in rat hepatobiliary function following treatment with acetone, 2-butanone, 2-hexanone, mirex, or chlordecone and subsequently exposed to chloroform.
Ayotte, P; Hewitt, LA; Plaa, GL, 1986
)
0.48
"Adrenal ornithine decarboxylase (ODC) is greatly elevated in rats dosed once with one of several insecticides; chlordecone, p,p'DDT or permethrin."( Modulation of adrenal ornithine decarboxylase by chlordecone, p,p'DDT and permethrin.
Bondy, SC; Hong, JS, 1987
)
0.74
"75 microM in 5 microliters NaCl) decreased the peak tremor power due to subsequently administered DDT, while increasing the tremor response in rats later dosed with chlordecone."( Pharmacological modification of tremor and enhanced acoustic startle by chlordecone and p,p'-DDT.
Gallus, JA; Herr, DW; Tilson, HA, 1987
)
0.7
" Dose-response experiments showed that the hepatocarcinogenic effects of long-term chlordecone administration became undetectable at concentrations in non-initiated rat liver in the same range as those measured in human biopsies taken from exposed workers who exhibited no liver effects."( Evaluation of chlordecone in a two-stage model of hepatocarcinogenesis: a significant sex difference in the hepatocellular carcinoma incidence.
Blanke, RV; Fitzgerald, R; Guzelian, PS; Sirica, AE; Wilkerson, CS; Wu, LL, 1989
)
0.86
" The onset of tremors was evident as early as 2 hr in 50 mg/kg dosed rats."( Acute chlordecone toxicity in rats: a relationship between tremor and ATPase activities.
Desaiah, D; Grice, T; Jordan, JE; Mishra, SK, 1981
)
0.74
" Body weight loss was significant by 90 days of dosing with 30 ppm chlordecone; no weight change was seen at the lower dose."( Neurobehavioral changes in adult Fischer 344 rats exposed to dietary levels of chlordecone (Kepone): a 90-day chronic dosing study.
Squibb, RE; Tilson, HA, 1982
)
0.73
" The battery of tests was administered on eight occasions, that is, before, at three-week intervals during dosing (PO or IP, five days each week for 15 weeks), and at three and six weeks after dosing."( Assessment of chemicals using a battery of neurobehavioral tests: a comparative study.
Mitchell, CL; Pryor, GT; Tilson, HA; Uyeno, ET,
)
0.13
"These studies were designed to provide dose-response relationships for chlordecone (CD) potentiation of BrCCl3 hepatotoxicity in male rats using biochemical, functional and histopathological parameters."( Potentiation of bromotrichloromethane hepatotoxicity and lethality by chlordecone preexposure in the rat.
Agarwal, AK; Mehendale, HM,
)
0.6
" Male Sprague-Dawley rats dosed once with chlordecone at 100 mg/kg were sacrificed after 24 hr, then brain norepinephrine (NE) and dopamine (DA) levels were assayed."( Lack of effects of chlordecone on synthesis rates, steady state levels and metabolites of catecholamines in rat brain.
Aldous, CN; Chetty, CS; Desaiah, D; Mehendale, HM, 1984
)
0.86
" On the basis of the distinct and integrative roles of EPR and SPR in liver responses to toxic injury, a generalized framework is presented that facilitates prediction of both toxic outcome, including shape of dose-response functions and interspecies variation to chemically induced liver damage."( A review of the role of tissue repair as an adaptive strategy: why low doses are often non-toxic and why high doses can be fatal.
Calabrese, EJ; Mehendale, HM, 1996
)
0.29
" Based on Monte Carlo simulation, which was used to run electronically 1000 lethality experiments for each dosing situation, the LD50 estimates for CCl4 toxicity with and without Kepone pretreatment were 47 and 2890 microliters/kg, respectively."( Physiologically based pharmacokinetic/pharmacodynamic modeling of the toxicologic interaction between carbon tetrachloride and Kepone.
Andersen, ME; Benjamin, SA; Constan, AA; el-Masri, HA; Mehendale, HM; Phillips, JK; Sabados, GR; Thomas, RS; Yang, RS, 1996
)
0.29
"The objective of this study was to evaluate the effect of age and dosage on percutaneous absorption and disposition of [14C]chlordecone (Kepone) and to describe results using a physiological based pharmacokinetic (PBPK) model."( Percutaneous absorption and disposition of [14C]chlordecone in young and adult female rats.
Fisher, HL; Hall, LL; Heatherington, AC; Shah, PV; Sumler, MR; Waller, CL, 1998
)
0.76
" To test this hypothesis, cycling female CD-1 mice (39 days) were dosed with MXC (8, 16, or 32 mg/kg/day), kepone (KPN, 8 mg/kg/day, positive control), or sesame oil (vehicle control) via intraperitoneal injection for 10 or 20 days."( Methoxychlor may cause ovarian follicular atresia and proliferation of the ovarian epithelium in the mouse.
Borgeest, C; Flaws, JA; Hoyer, PB; Mayer, LP; Symonds, D, 2002
)
0.31
" Ovariectomized (NZBxNZW)F(1) mice were treated for 6 weeks with implanted sustained-release pellets containing chlordecone or E2 at dosing rates shown previously to significantly shorten time to onset of disease."( Comparison of chlordecone and estradiol effects on splenic T-cells in (NZBxNZW)F(1) mice.
Butfiloski, EJ; Roberts, SM; Sobel, ES; Wang, F, 2008
)
0.92
" In addition, the bioaccumulation of CLD was measured in the muscle tissue of Macrobrachium rosenbergii to underline potential dose-response relationship."( Effects of chlordecone on 20-hydroxyecdysone concentration and chitobiase activity in a decapod crustacean, Macrobrachium rosenbergii.
Boulangé-Lecomte, C; Caupos, F; Dodet, N; Forget-Leray, J; Geraudie, P; Gismondi, E; Lafontaine, A; Lagadic, L; Lemoine, S; Thomé, JP, 2016
)
0.82
" We have observed non-monotonic dose-response curves, which agree with endocrine-disrupting chemical effects."( Multi-scale impact of chronic exposure to environmental concentrations of chlordecone in freshwater cnidarian, Hydra circumcincta.
Abraldes, J; Benbrahim, K; Cerini, C; Colpaert, R; de Jong, L; Mambert, M; Moreau, X; Pique, V; Robin, M; Villard, PH, 2020
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
persistent organic pollutantAny environmental contaminant that is resistant to environmental degradation through photolytic, biological or chemical processes. Such substances can have significant impact on health and the environment, as they persist in the environment, bioaccumulate in animal tissue and so biomagnify in food chains.
insecticideStrictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
cyclic ketone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (88)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.79430.003245.467312,589.2998AID2517
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
glp-1 receptor, partialHomo sapiens (human)Potency4.46680.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency100.00000.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency20.69780.012610.691788.5700AID887
pregnane X receptorRattus norvegicus (Norway rat)Potency76.55340.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency45.00913.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.86040.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency51.78750.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency51.78750.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency17.35820.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency28.65230.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency46.41240.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency15.84890.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency47.90530.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency40.87070.00137.762544.6684AID2120
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.92440.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency53.78000.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.04140.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency54.76140.000417.946075.1148AID1346784; AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency44.71760.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency36.43780.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.30630.000817.505159.3239AID1159527; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency51.35580.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency41.77690.375827.485161.6524AID588526; AID588527; AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency11.82190.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency41.87760.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency46.06250.001024.504861.6448AID588534; AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency49.03270.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency47.40110.023723.228263.5986AID588541; AID588543; AID743223; AID743241
caspase-3Homo sapiens (human)Potency47.90530.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency16.36010.005210.865235.4813AID686970
aryl hydrocarbon receptorHomo sapiens (human)Potency79.43280.000723.06741,258.9301AID651777
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency39.51320.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency34.76500.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency51.87640.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency27.85600.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency51.616719.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency34.37180.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency110.38700.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency62.90390.006723.496068.5896AID1346980
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency15.93700.316212.443531.6228AID902; AID924
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency22.38721.000012.232631.6228AID1452
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency35.60560.010039.53711,122.0200AID588545; AID588547
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency100.00003.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency22.98330.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency62.90390.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency11.17680.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency51.87640.042027.378961.6448AID743210; AID743228
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency40.07494.466824.832944.6684AID651749
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency46.33720.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency27.00500.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624296
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.92440.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency62.90390.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency65.79620.002319.595674.0614AID651631; AID651743; AID720552
Integrin beta-3Homo sapiens (human)Potency0.25120.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency0.25120.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency62.90390.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Nuclear receptor ROR-gammaHomo sapiens (human)Potency10.01510.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency62.90390.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency62.90390.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)12.02260.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorOvis aries (sheep)Kd0.49000.49002.03755.9000AID69702
Estrogen receptor betaOvis aries (sheep)Kd0.49000.49002.03755.9000AID69702
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC502.68500.19503.667918.6960AID540270
heat shock protein 90, putativePlasmodium falciparum 3D7AC502.93000.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (238)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID69702Displacement of [3H]-estradiol (E2) from sheep uterine estrogen receptor2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID680520TP_TRANSPORTER: inhibition of Doxorubicin efflux (Doxorubicin: 50 uM, Chlordecone: 250 uM) in MDR1-expressing B16/F10 cells1996Toxicology and applied pharmacology, Nov, Volume: 141, Issue:1
Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (527)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990260 (49.34)18.7374
1990's74 (14.04)18.2507
2000's42 (7.97)29.6817
2010's96 (18.22)24.3611
2020's55 (10.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.18 (24.57)
Research Supply Index6.36 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index79.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.17%)5.53%
Reviews31 (5.36%)6.00%
Case Studies3 (0.52%)4.05%
Observational0 (0.00%)0.25%
Other543 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]